Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Silodosin - Kissei Pharmaceutical

Drug Profile

Silodosin - Kissei Pharmaceutical

Alternative Names: KAD 3213; KMD-3213; KSO-0400; Rapaflo; Silodyx; Thrupas; Urief; Urief OD; Urorec

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer AbbVie; Actavis; Almirall S.A.; Daiichi Sankyo Company; Eisai Co Ltd; JW Pharmaceutical; Kissei Pharmaceutical; Mayne Pharma Group; Pharmaplan; Recordati; Synmosa Biopharma; Zambon France
  • Class Benzamides; Indoles; Muscle relaxants; Small molecules; Urologics
  • Mechanism of Action Alpha-1a adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase II Urinary calculi
  • No development reported Nocturia; Prostatitis

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 06 Aug 2019 Launched for Benign prostatic hyperplasia in Malaysia before August 2019 (PO) (Kissei Pharmaceutical pipeline August 2019)
  • 06 Aug 2019 Launched for Benign prostatic hyperplasia in Myanmar (PO) (Kissei Pharmaceutical pipeline August 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top